TScan Therapeutics (NASDAQ:TCRX) Given "Buy" Rating at Needham & Company LLC

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. Wedbush restated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday, March 5th. Morgan Stanley reissued an "overweight" rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday, March 6th. Finally, Barclays decreased their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of "Buy" and an average price target of $9.33.

TScan Therapeutics Trading Up 9.7 %

TScan Therapeutics stock traded up $0.11 during trading on Tuesday, hitting $1.24. The company's stock had a trading volume of 346,807 shares, compared to its average volume of 348,970. The stock's fifty day moving average is $1.74 and its 200 day moving average is $3.24. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $9.69. The stock has a market capitalization of $70.17 million, a price-to-earnings ratio of -1.17 and a beta of 1.09.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $1.43 million. As a group, equities research analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in TCRX. Stifel Financial Corp boosted its position in TScan Therapeutics by 3.9% in the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company's stock valued at $494,000 after buying an additional 3,733 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after acquiring an additional 4,852 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares during the last quarter. Wellington Management Group LLP grew its stake in TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company's stock valued at $404,000 after purchasing an additional 6,550 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in TScan Therapeutics by 6.7% during the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company's stock worth $352,000 after purchasing an additional 7,282 shares during the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.